Neuronetics Receives FDA Clearance For Transcranial Magnetic Stimulation System For Depression

19 Jul 2022

About 50% of the 13.9 million people undergoing treatment in the US for major depressive disorder have anxious depression, which represents a large market opportunity for Neuronetics, according to an analyst.

Neuronetics, Inc. announced on 19 July the US Food and Drug Administration cleared its NeuroStar transcranial magnetic stimulation system (TMS) for anxious depression based on results from a real-world study. The system was previously cleared to treat obsessive-compulsive disorder.

BTIG analyst Marie Thibault wrote in her 19 July report that the extended label is a “positive update that, along...